These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16401659)

  • 41. Physical symptoms comorbid with depression and the new antidepressant duloxetine.
    Bailey KP
    J Psychosoc Nurs Ment Health Serv; 2003 Dec; 41(12):13-8. PubMed ID: 14682027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does the new antidepressant duloxetine (Cymbalta) have any advantages over other antidepressant drugs?
    Miller MC
    Harv Ment Health Lett; 2004 Nov; 21(5):8. PubMed ID: 15556908
    [No Abstract]   [Full Text] [Related]  

  • 43. [Stress incontinence in general practice].
    Krankenpfl J; 2004; 42(7-10):228-9. PubMed ID: 15675390
    [No Abstract]   [Full Text] [Related]  

  • 44. SNRIs in the management of acute major depressive disorder.
    Zajecka JM; Albano D
    J Clin Psychiatry; 2004; 65 Suppl 17():11-8. PubMed ID: 15600377
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder.
    Brecht S; Kajdasz D; Ball S; Thase ME
    Int Clin Psychopharmacol; 2008 Nov; 23(6):317-24. PubMed ID: 18854719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Duloxetine treatment of Premenstrual Dysphoric Disorder: case reports.
    Ramos MG; Hara C; Rocha FL
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):579-80. PubMed ID: 17897763
    [No Abstract]   [Full Text] [Related]  

  • 47. Duloxetine: a review of its pharmacology and use in chronic pain management.
    Bellingham GA; Peng PW
    Reg Anesth Pain Med; 2010; 35(3):294-303. PubMed ID: 20921842
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Duloxetine-induced cutaneous adverse reaction.
    Oulis P; Masdrakis VG; Karakatsanis NA; Karapoulios E; Kouzoupis AV; Soldatos CR
    J Clin Psychopharmacol; 2008 Feb; 28(1):104-5. PubMed ID: 18204353
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
    Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
    J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Duloxetine (Yentreve) in the general practice test: recommendation by the experts. Effective and tolerable therapy of symptoms in female stress incontinence].
    Krankenpfl J; 2005; 43(7-10):189-90. PubMed ID: 16515261
    [No Abstract]   [Full Text] [Related]  

  • 51. Open-label support for duloxetine for the treatment of panic disorder.
    Simon NM; Kaufman RE; Hoge EA; Worthington JJ; Herlands NN; Owens ME; Pollack MH
    CNS Neurosci Ther; 2009; 15(1):19-23. PubMed ID: 19228176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Manic switching in patients receiving duloxetine.
    de Dios C; Ezquiaga E
    Am J Psychiatry; 2007 Jul; 164(7):1121. PubMed ID: 17606669
    [No Abstract]   [Full Text] [Related]  

  • 54. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial.
    Mico' U; Bruno A; Pandolfo G; Maria Romeo V; Mallamace D; D'Arrigo C; Spina E; Zoccali RA; Muscatello MR
    Int Clin Psychopharmacol; 2011 Nov; 26(6):303-10. PubMed ID: 21934625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluoxetine normalizes increased cardiac vagal tone in bulimia nervosa.
    Rissanen A; Naukkarinen H; Virkkunen M; Rawlings RR; Linnoila M
    J Clin Psychopharmacol; 1998 Feb; 18(1):26-32. PubMed ID: 9472839
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function.
    Ravindran LN; Eisfeld BS; Kennedy SH
    J Clin Psychopharmacol; 2008 Feb; 28(1):107-8. PubMed ID: 18204355
    [No Abstract]   [Full Text] [Related]  

  • 57. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.
    Häuser W; Urrútia G; Tort S; Uçeyler N; Walitt B
    Cochrane Database Syst Rev; 2013 Jan; (1):CD010292. PubMed ID: 23440848
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults.
    Mariappan P; Ballantyne Z; N'Dow JM; Alhasso AA
    Cochrane Database Syst Rev; 2005 Jul; (3):CD004742. PubMed ID: 16034945
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The development of new antidepressants: focus on duloxetine and escitalopram.
    Huffman JC; Perlis RH
    Harv Rev Psychiatry; 2003; 11(1):30-6. PubMed ID: 12866739
    [No Abstract]   [Full Text] [Related]  

  • 60. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.
    Berk M; du Plessis AD; Birkett M; Richardt D
    Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.